Beta-blockade in heart failure: selective versus nonselective agents - PubMed (original) (raw)

Review

Beta-blockade in heart failure: selective versus nonselective agents

M Metra et al. Am J Cardiovasc Drugs. 2001.

Abstract

Controlled clinical trials performed in more than 13 000 patients have, to date, consistently shown the beneficial effects of long term beta-adrenoceptor antagonist (beta-blocker) therapy in patients with chronic heart failure. It is not clear whether this represents a class effect or whether it is specific only to some agents. Beneficial effects on the prognosis of patients with mild to moderate heart failure have been shown with metoprolol, bisoprolol, and carvedilol. These beta-blockers, however, differ in their pharmacologic characteristics. Metoprolol and bisoprolol are selective for beta(1)-adrenergic receptors and are devoid of ancillary properties. Carvedilol, at a dosage of 50 mg/day, blocks all beta(1)-, beta(2)-, and alpha(1)-adrenergic receptors, and it has associated antiproliferative and antioxidant activities. These differences cause a varied acute hemodynamic response, with a reduction in cardiac output and a tendency toward a rise in pulmonary wedge pressure with selective agents and no change in cardiac output and a slight decrease in pulmonary pressures with carvedilol. Accordingly, when the therapy is started, the most frequent adverse effects are worsening heart failure with metoprolol and bisoprolol, and hypotension and dizziness with carvedilol. It remains controversial whether these differences also influence the long term effects of therapy. Carvedilol may provide a more comprehensive blockade of the cardiac adrenergic drive than selective beta-blockers because it does not upregulate beta(1)-adrenergic receptors, blocks all adrenergic receptors and decreases cardiac norepinephrine release. These properties may lead to a larger increase in left ventricular function and a lack of improvement in maximal exercise capacity with carvedilol, compared with selective beta-blockers. It is, however, unclear whether these differences also influence patient outcome. The long term effects of different beta-blockers on prognosis are currently being compared in the Carvedilol or Metoprolol European Trial (COMET) in which more than 3000 patients with chronic heart failure have been randomized in a 1 : 1 ratio to receive metoprolol or carvedilol.

PubMed Disclaimer

Cited by

Carvedilol: a review of its use in chronic heart failure.
Keating GM, Jarvis B. Keating GM, et al. Drugs. 2003;63(16):1697-741. doi: 10.2165/00003495-200363160-00006. Drugs. 2003. PMID: 12904089 Review.
Beta-blockers in heart failure: are pharmacological differences clinically important?
Metra M, Cas LD, di Lenarda A, Poole-Wilson P. Metra M, et al. Heart Fail Rev. 2004 Apr;9(2):123-30. doi: 10.1023/B:HREV.0000046367.99002.a4. Heart Fail Rev. 2004. PMID: 15516860 Review.
Model-based meta-analysis of changes in circulatory system physiology in patients with chronic heart failure.
Takaoka R, Soejima Y, Guro S, Yoshioka H, Sato H, Suzuki H, Hisaka A. Takaoka R, et al. CPT Pharmacometrics Syst Pharmacol. 2021 Sep;10(9):1081-1091. doi: 10.1002/psp4.12676. Epub 2021 Jul 16. CPT Pharmacometrics Syst Pharmacol. 2021. PMID: 34218511 Free PMC article.
Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBIS-ELD trial.
Düngen HD, Apostolovic S, Inkrot S, Tahirovic E, Töpper A, Mehrhof F, Prettin C, Putnikovic B, Neskovic AN, Krotin M, Sakac D, Lainscak M, Edelmann F, Wachter R, Rau T, Eschenhagen T, Doehner W, Anker SD, Waagstein F, Herrmann-Lingen C, Gelbrich G, Dietz R; CIBIS-ELD investigators and Project Multicentre Trials in the Competence Network Heart Failure. Düngen HD, et al. Eur J Heart Fail. 2011 Jun;13(6):670-80. doi: 10.1093/eurjhf/hfr020. Epub 2011 Mar 23. Eur J Heart Fail. 2011. PMID: 21429992 Free PMC article. Clinical Trial.

Beta-blockade in heart failure: selective versus nonselective agents - PubMed (original) (raw)